Firstly, this represents a study evaluating, in a large cohort of patients undergoing neoadjuvant chemotherapy, HER2 expression evolution from primary breast cancer to residual disease by incorporating the up-and-coming category of HER2-low-positive breast cancer. The gene discussed is ERBB2; the disease is breast cancer.